1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Zhaoke Ophthalmology Limited

Zhaoke Ophthalmology Limited

6622.HK
Zhaoke Ophthalmology LimitedHK flagHong Kong Stock Exchange
2.65
HKD
+0.05
- -
1.45BMarket Cap
Zhaoke Ophthalmology Limited
6622.HK
(Hong Kong Stock Exchange)

Recent

price

2.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
0.03
0.13
0.06
Revenue per Share
-0.23
-1.36
-5.16
-0.75
-0.71
-0.43
-0.38
Basic EPS, GAAP
-0.15
-0.52
-0.82
-1.05
-0.77
-0.55
-0.48
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.31
-1.67
- -
-6.33
-7
-7.39
-7.75
Book Value per Share
-0.12
-1.65
5.66
3.71
3.04
2.72
2.18
Tangible Book Value per Share
535
535
412
542
544
546
547
Basic Weighted Avg Shares
- -
- -
- -
- -
19
69
32
Sales/Revenue/Turnover
- -
- -
- -
- -
-2,409.11
-411.94
-861.56
Operating Margin (%)
17
20
26
35
49
54
52
Depreciation Expense
-122
-727
-2,130
-407
-385
-237
-209
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
-2,053.54
-342.58
-653.6
Profit Margin (%)
196
860
2,120
1,778
1,458
1,302
1,045
Working Capital
26
23
21
28
22
16
9
LT Debt
-26
-746
2,495
2,348
2,048
1,900
1,576
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-95.5%
-17.06%
Free Cash Flow
- -
4.58%
-11%
Net Income, GAAP
- -
11.26%
-12%
Sales/Revenue/Turnover
- -
- -
-53.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
19
2024
- -
- -
- -
- -
69
2025
- -
- -
- -
- -
32

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.71
2024
- -
- -
- -
- -
-0.43
2025
- -
- -
- -
- -
-0.38

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
ARS Pharmaceuticals, Inc. (SPRY)
Unicycive Therapeutics, Inc. (UNCY)
ESSA Pharma Inc. (EPIX)
Awakn Life Sciences Corp. (AWKN.NE)
Bio-Works Technologies AB (publ) (BIOWKS.ST)
Peak Bio, Inc. (PKBOW)
Business
Zhaoke Ophthalmology Limited (SEHK: 6622) is a Cayman Islands-incorporated ophthalmic pharmaceutical company founded in 2017 and headquartered in Nansha, Guangzhou, People's Republic of China, that engages in the research, development, manufacturing, and commercialization of therapies addressing major eye diseases across the anterior and posterior segments, including dry eye disease (DED), myopia, presbyopia, wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and glaucoma. The company maintains a fully integrated platform with a state-of-the-art production facility in Nansha and offers a comprehensive pipeline of 13 innovative drugs and 12 generic drugs; flagship innovative assets include Cyclosporine A (CsA) Ophthalmic Gel and NVK-002 (Atropine Sulfate Eye Drops) for DED under NDA review with NMPA, TAB014 (Bevacizumab Intravitreal Injection) in Phase III for wAMD, BRIMOCHOL™ PF in preparation for Phase III for presbyopia, and ZKY001 for corneal epithelial defects, alongside generic offerings targeting broader patient access. Zhaoke Ophthalmology primarily serves the Chinese market with expansion into ASEAN, South Korea, Hong Kong, the GCC, Middle East, and Indonesia through strategic partnerships, including its second collaboration with PT Ferron in November 2025 for BRIMOCHOL™ PF commercialization in Indonesia, agreements with Jamjoom Pharmaceuticals in June 2025 for CsA Ophthalmic Gel in the Middle East, Lunatus in March 2025 for BRIMOCHOL™ PF in the GCC, Somerset Therapeutics and FAREVA in June-July 2025 for manufacturing and global supply, and Seefunge in early 2025 for joint product launches; these alliances support its global growth strategy while advancing near-term commercialization goals.